RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+15.35%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$561M
AUM Growth
+$561M
(+63%)
Cap. Flow
+$171M
Cap. Flow
% of AUM
30.54%
Top 10 Holdings %
Top 10 Hldgs %
29%
Holding
100
New
15
Increased
49
Reduced
16
Closed
11
Top Buys
| 1 |
Merck
MRK
|
$12.6M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$12.3M |
| 3 |
Universal Health Services
UHS
|
$10.2M |
| 4 |
Amgen
AMGN
|
$9.56M |
| 5 |
Nektar Therapeutics
NKTR
|
$8.34M |
Top Sells
| 1 |
Universal Technical Institute
UTI
|
$6.79M |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
$5.83M |
| 3 |
Gilead Sciences
GILD
|
$4.63M |
| 4 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
$4.37M |
| 5 |
CELG
Celgene Corp
CELG
|
$3.57M |
Sector Composition
| 1 | Healthcare | 88.44% |
| 2 | Financials | 0.78% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $19.9M | 3.36% | 114,978 +70,978 | +161% | +$12.3M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $17.4M | 2.94% | 151,000 -31,000 | -17% | -$3.57M |
|
|
3
Merck
MRK
$210B
| $17.2M | 2.91% | 300,000 +220,000 | +275% | +$12.6M |
|
4
Biogen
BIIB
$19.4B
| $17.2M | 2.9% | 40,700 +19,200 | +89% | +$8.11M |
|
|
5
Amgen
AMGN
$155B
| $15.8M | 2.67% | 99,000 +59,832 | +153% | +$9.56M |
|
6
Alkermes
ALKS
$4.78B
| $15.7M | 2.65% | 258,000 +115,000 | +80% | +$7.01M |
|
|
7
Gilead Sciences
GILD
$140B
| $15.6M | 2.63% | 159,000 -47,138 | -23% | -$4.63M |
|
8
UnitedHealth
UNH
$281B
| $15.4M | 2.59% | 130,000 +63,000 | +94% | +$7.45M |
|
9
CVS Health
CVS
$92.8B
| $15M | 2.52% | 145,000 +48,000 | +49% | +$4.95M |
|
|
AGN
10
DELISTED
Allergan plc
AGN
| $13.5M | 2.27% | 45,300 +18,300 | +68% | +$5.45M |
|
11
AbbVie
ABBV
$372B
| $12.9M | 2.17% | 220,000 +80,000 | +57% | +$4.68M |
|
12
Cardinal Health
CAH
$35.5B
| $12.8M | 2.15% | 141,400 +71,400 | +102% | +$6.45M |
|
13
Esperion Therapeutics
ESPR
$448M
| $11.8M | 1.98% | 126,926 -23,074 | -15% | -$2.14M |
|
|
RAD
14
DELISTED
Rite Aid Corporation
RAD
| $11.1M | 1.87% | 1,276,462 +491,462 | +63% | +$4.27M |
|
15
Incyte
INCY
$16.5B
| $11M | 1.85% | 120,000 +76,000 | +173% | +$6.97M |
|
|
16
Nektar Therapeutics
NKTR
$568M
| $11M | 1.85% | 996,600 +758,600 | +319% | +$8.34M |
|
|
17
Universal Health Services
UHS
$11.6B
| $10.2M | 1.73% | +87,000 | New | +$10.2M |
|
18
Regeneron Pharmaceuticals
REGN
$61.5B
| $9.93M | 1.67% | 22,000 -500 | -2% | -$226K |
|
19
Jazz Pharmaceuticals
JAZZ
$7.75B
| $9.5M | 1.6% | 55,000 +37,600 | +216% | +$6.5M |
|
20
Eli Lilly
LLY
$657B
| $9.37M | 1.58% | 129,000 +63,000 | +95% | +$4.58M |
|
21
BioMarin Pharmaceuticals
BMRN
$11.2B
| $9.35M | 1.58% | 75,000 +14,000 | +23% | +$1.74M |
|
|
MDVN
22
DELISTED
MEDIVATION, INC.
MDVN
| $8.91M | 1.5% | 69,000 -1,700 | -2% | -$219K |
|
23
Elevance Health
ELV
$71.8B
| $8.8M | 1.48% | 57,000 +16,000 | +39% | +$2.47M |
|
24
McKesson
MCK
$85.4B
| $8.6M | 1.45% | 38,000 +22,000 | +138% | +$4.98M |
|
25
Bristol-Myers Squibb
BMY
$96B
| $8.32M | 1.4% | 129,000 +14,000 | +12% | +$903K |
|